This study explores the potential of state-of-the-art large language models (LLM) to scaffold type 1 diabetes management by automating the analysis of multimodal diabetes device data, including blood glucose, carbohydrate, and insulin. By conducting a series of empirically grounded data analysis tasks, such as detecting glycemic episodes, clustering similar episodes into patterns, identifying counterfactual days, and performing visual data analysis, we assess whether models like ChatGPT 4o, Claude 3.5 Sonnet, and Gemini Advanced can offer meaningful insights from diabetes data. Our findings show that ChatGPT 4o demonstrates strong potential in accurately interpreting data in the context of specific glycemic episodes, identifying glycemic patterns, and analyzing patterns. However, limitations in handling edge cases and visual reasoning tasks highlight areas for future development. Using LLMs to automate data analysis tasks and generate narrative summaries could scaffold clinical decision-making in diabetes management, which could make frequent data review feasible for improved patient outcomes.

The authors have declared no competing interest.

This study did not receive any funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors.